Drug Monograph

Drug Name: **Uptravi® (selexipag) vial**
Drug Class: **Respiratory: Pulmonary Arterial Hypertension-Persistent Pulmonary Hypertension Agents, Prostacyclins, IV/SQ**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Uptravi is now available as a solution for injection containing 1,800 mcg in a 10 ml single-dose vial.
Manufacturer:	Distributed by: Actelion Pharmaceuticals US, South San Francisco, CA 94080.
Indications:	Uptravi is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay the disease progression and reduce the risk of hospitalization for PAH. Use of Uptravi for injection is for patients who are temporarily unable to take oral therapy.
Costs:	$320 per 10 ml vial containing 1,800 mcg of Uptravi. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation:	☐ Clinical Edit ☐ Open Access	☐ PA Required ☒ PDL
Type of PA Criteria:	☐ Appropriate Indications ☐ No PA Required	☒ Non-Preferred ☐ Preferred

Prepared by: April Ash, PharmD
Date: September 2, 2021